Adults with poorly controlled type 2 diabetes assigned higher, investigational doses of the GLP-1 receptor agonist dulaglutide experienced greater improvements in glycemic response and body weight ...
Results from the phase 3 AWARD-11 trial evaluating higher doses of dulaglutide showed superior HbA1c and body weight reductions with an investigational 4.5mg dose in patients with type 2 diabetes (T2D ...
Tirzepatide, a dual incretin agonist of the glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors, has favorable effects on glycemic control and body weight. The effects ...
BARCELONA, Spain — Dulaglutide (Trulicity, Lilly) treatment reduces binge eating in patients with type 2 diabetes and binge eating disorder, and was associated with rapid and significant reductions in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results